Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Bioporto

Bioporto
1917 FOUNDED
PUBLIC STATUS
31-40 EMPLOYEES
BIOPOR STOCK SYMBOL
$0.40 SHARE PRICE (As of Friday Closing)
Description

Bioporto A/S is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's segments include the NGAL Test, ELISA Human NGAL kits, ELISA Animal NGAL kits, ELISA MBL kits, Antibodies, and Other products and licenses. Bioporto generates majority of its revenues from Antibodies segment.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Medical Supplies
Other Industries
Pharmaceuticals
Stock Exchange
CSE
Primary Office
  • Grusbakken 8
  • Tuborg Havnevej 15 Street
  • 2900 Hellerup
  • Denmark

+45 45 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Bioporto’s full profile, request a free trial.

Bioporto Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.36 - $0.72 $69.6M $0.39 -$0.05 208K 175M

Bioporto Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 94,496 86,753 80,472 35,852
Revenue 4,221 4,118 3,813 3,078
EBITDA (7,802) (6,500) (5,541) (3,645)
Net Income (7,720) (6,023) (4,887) (3,386)
Total Assets 11,641 10,141 10,572 7,166
Total Debt 608 22 29 40
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bioporto Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Bioporto‘s full profile, request access.

Request full access to PitchBook

Bioporto Executive Team (3)

Name Title Board
Seat
Contact
Info
Peter Eriksen Chief Executive Officer
Ole Larsen Chief Financial Officer
Jan Andersen Chief Operating Officer